论文部分内容阅读
自武田(Takeda)公司产品硼替佐米(bortezomib,Velcade)于2003年获准上市以来,蛋白酶体抑制剂已成为多发性骨髓瘤治疗的主要用药。武田公司日前又在美国和欧洲递交了同类新药ixazomib的上市申请,使其上市进程更近一步,而该药物可能成为此类药物中的首个口服治疗药物。虽然武田公司非常希望能在2017年5月Velcade专利到期前大力推动ixazomib替代Velcade的进程,以维护其在多发性骨髓瘤治疗市场的地位,但要让医生接受这一新型口服药物,还需要更多临床数据,尤其是一线治疗数据的支持。主要介绍ixazomib用于治疗复发性多发性骨髓瘤以及作为多发性骨髓瘤一线治疗药物的若干临床研究,解析并展望多发性骨髓瘤治疗市场。
Since the Takeda company’s bortezomib (Velcade) was approved in 2003, proteasome inhibitors have become the mainstay of treatment for multiple myeloma. Takeda recently filed a listing application for ixazomib, a new drug of its kind in the United States and Europe, bringing the marketer to the next level and the drug may become the first oral therapeutic drug in the class. Although Takeda is keen to push ixazomib to replace Velcade before the Velcade patent expires in May 2017 in order to maintain its position in the treatment of multiple myeloma, it will be necessary for the physician to accept the new oral drug More clinical data, especially first-line treatment data support. Mainly introduced ixazomib for the treatment of recurrent multiple myeloma and as a first-line treatment of multiple myeloma, a number of clinical studies, analysis and look forward to the treatment of multiple myeloma market.